Kathryn Hockemeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kathryn Hockemeyer has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Aristotelis Tsirigos
Department of Pathology, New York University Grossman School of Medicine, New York, USA
21 shared publications - Iannis Aifantis
Department of Pathology, NYU Grossman School of Medicine, New York, USA
21 shared publications - Jochen Imig
Max-Planck-Institute for Molecular Physiology , Otto-Hahn-Str. 11, 44227 Dortmund
20 shared publications - Eleazar Vega-Saenz de Miera
Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA
19 shared publications - Eric Wang
The Jackson Laboratory for Genomic Medicine
19 shared publications - Iman Osman
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
19 shared publications
Latest Publications
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Melanoma being one of the most common and deadliest skin cancers has been increasing since the past decade. Patients at advanced stages of the disease have very poor prognoses, as opposed to at the earlier stages. Nowadays, the standard of care of advanced melanoma is resection, followed by immune checkpoint inhibition–based immunotherapy. However, a substantial proportion of patients either do not respond or develop resistance. This underscores a need for novel approaches and therapeutic targets as well as a better understanding of the mechanisms of melanoma pathogenesis. Long noncoding RNAs (lncRNA) comprise a poorly characterized class of functional players and promising targets in promoting malignancy. Certain lncRNAs have been identified to play integral roles in melanoma progression and drug resistance; however, systematic screens to uncover novel functional lncRNAs are scarce. In this study, we profile differentially expressed lncRNAs in patient-derived short-term metastatic cultures and BRAF–MEK inhibition–resistant cells. We conduct a focused growth-related CRISPR inhibition screen of overexpressed lncRNAs, validate, and functionally characterize lncRNA hits with respect to cellular growth, invasive capacities, and apoptosis in vitro as well as the transcriptomic impact of our lead candidate the novel lncRNA XLOC_030781. In sum, we extend the current knowledge of ncRNAs and their potential relevance in melanoma.Significance:LncRNAs have emerged as novel players in regulating many cellular aspects also in melanoma. The number of functional significances of most lncRNAs remains elusive. We provide a comprehensive strategy to identify functionally relevant lncRNAs in melanoma by combining expression profiling with CRISPR inhibition growths screens. Our results broaden the characterized lncRNAs as potential targets for future therapeutic applications.
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Melanoma being one of the most common and deadliest skin cancers has been increasing since the past decade. Patients at advanced stages of the disease have very poor prognoses, as opposed to at the earlier stages. Nowadays, the standard of care of advanced melanoma is resection, followed by immune checkpoint inhibition–based immunotherapy. However, a substantial proportion of patients either do not respond or develop resistance. This underscores a need for novel approaches and therapeutic targets as well as a better understanding of the mechanisms of melanoma pathogenesis. Long noncoding RNAs (lncRNA) comprise a poorly characterized class of functional players and promising targets in promoting malignancy. Certain lncRNAs have been identified to play integral roles in melanoma progression and drug resistance; however, systematic screens to uncover novel functional lncRNAs are scarce. In this study, we profile differentially expressed lncRNAs in patient-derived short-term metastatic cultures and BRAF–MEK inhibition–resistant cells. We conduct a focused growth-related CRISPR inhibition screen of overexpressed lncRNAs, validate, and functionally characterize lncRNA hits with respect to cellular growth, invasive capacities, and apoptosis in vitro as well as the transcriptomic impact of our lead candidate the novel lncRNA XLOC_030781. In sum, we extend the current knowledge of ncRNAs and their potential relevance in melanoma.Significance:LncRNAs have emerged as novel players in regulating many cellular aspects also in melanoma. The number of functional significances of most lncRNAs remains elusive. We provide a comprehensive strategy to identify functionally relevant lncRNAs in melanoma by combining expression profiling with CRISPR inhibition growths screens. Our results broaden the characterized lncRNAs as potential targets for future therapeutic applications.
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
TCGA XLOC_030781 expression data analysis in cancer and clinical melanoma samples. A, Pan-cancer expression analysis using TCGA. SKCM, skin cutaneous melanoma. B, UCSC genome browser snap shots of H3K27ac ChIP-seq data from melanoma (MM, black), non-malignant skin biopsies (NHM, black), foreskin sample (green), and other malignant samples (other colors) at the XLOC_030781/ENSG00000287723 locus. Pink bar shows the peak area of interest in the vicinity of XLOC_030781 promoter. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse Large B-cell Lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney Chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, low grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
TCGA XLOC_030781 expression data analysis in cancer and clinical melanoma samples. A, Pan-cancer expression analysis using TCGA. SKCM, skin cutaneous melanoma. B, UCSC genome browser snap shots of H3K27ac ChIP-seq data from melanoma (MM, black), non-malignant skin biopsies (NHM, black), foreskin sample (green), and other malignant samples (other colors) at the XLOC_030781/ENSG00000287723 locus. Pink bar shows the peak area of interest in the vicinity of XLOC_030781 promoter. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse Large B-cell Lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney Chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, low grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
TCGA metaanalysis of lncRNA XLOC_030781
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
TCGA metaanalysis of lncRNA XLOC_030781
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
LncRNA candidate selection for CRISPRi screen and expression of lncRNAs associated to melanomagenesis. A, Flow diagram of integrated RNA- and ChIP-seq for the preselection of lncRNAs. Selection parameters are FDR < 5%, log fc > 0.75, and CPM > 1 in higher expressed cell type, either histone mark (H3K4me3 or H3K27ac) in the higher expressed cell type; no mono-exonic lncRNAs and log fc ≥ 0.5 between investigated cell type and either WM1361a or 501mel. B, Heatmap of differentially expressed lncRNAs by RNA-seq in patient/donor-derived melanocytes (n = 4) and metastatic STCs (BM, brain metastasis, n = 5; LN, lymph node metastasis, n = 4) and melanoma cell lines 501mel (n = 4) and WM1361a (n = 3). C, Heatmap showing differential lncRNA expression in the SK-Mel239 parental melanoma cell line versus BRAF and 1059 MEKi-resistant cell line (n = 2). D, Boxplot showing the log2 CPM expression of selected melanoma-associated lncRNAs SAMMSON, MEG3, H19, and PCAT1 in melanocytes (n = 4), brain metastasis (n = 5), and LN STCs (n = 4) detected by RNA-seq. DE, differentially expressed; Mets, metastasis; TSS, transcription start site.
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
LncRNA candidate selection for CRISPRi screen and expression of lncRNAs associated to melanomagenesis. A, Flow diagram of integrated RNA- and ChIP-seq for the preselection of lncRNAs. Selection parameters are FDR < 5%, log fc > 0.75, and CPM > 1 in higher expressed cell type, either histone mark (H3K4me3 or H3K27ac) in the higher expressed cell type; no mono-exonic lncRNAs and log fc ≥ 0.5 between investigated cell type and either WM1361a or 501mel. B, Heatmap of differentially expressed lncRNAs by RNA-seq in patient/donor-derived melanocytes (n = 4) and metastatic STCs (BM, brain metastasis, n = 5; LN, lymph node metastasis, n = 4) and melanoma cell lines 501mel (n = 4) and WM1361a (n = 3). C, Heatmap showing differential lncRNA expression in the SK-Mel239 parental melanoma cell line versus BRAF and 1059 MEKi-resistant cell line (n = 2). D, Boxplot showing the log2 CPM expression of selected melanoma-associated lncRNAs SAMMSON, MEG3, H19, and PCAT1 in melanocytes (n = 4), brain metastasis (n = 5), and LN STCs (n = 4) detected by RNA-seq. DE, differentially expressed; Mets, metastasis; TSS, transcription start site.
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Table S1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Table S1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
CRISPRi screen lncRNA hit functional characterization. A, Flow cytometry–based dotmplot showing GFP and mCherry signal as proxy for sgRNA and dCas9 expression (left). 7-AAD fluorescence–dependent cell cycle analysis in 501mel-dCas9-KRAB (top) and WM136a-dCas9-KRAB (bottom) cell lines upon sgBDNF-AS, sgXLOC_030781, and sgGMDS-AS1 CRISPRi knockdown (rigth). Note that the top panel is plotted linear and bottom logarithmic because of better cell cycle–gating parameters. B, Cell cycle phase quantification based on A in percent of cells (n = 2). C, PARP cleavage apoptosis assay performed by Western blotting upon sgBDNF-AS, sgXLOC_030781, and sgGMDS-AS1 knockdown in 501meld-Cas9-KRAB and WM1361a-dCas9-KRAB Representative Western blots (top). GAPDH detection was used as a loading control; densitometric quantification of apoptosis as cleaved PARP/GAPDH protein ratio (bottom; average of n = 2). sgROSA served as negative control and etoposide apoptosis inducer as positive control. D, Re-analysis of 7-AAD cell cycle assay staining using exact same gating parameters for sub-G1 cellular fraction indicative of apoptosis. E, Transwell cell migration assay. Fluorescence photomicrographs show calcein-stained migrated cells of sgBDNF-AS, sgGMDS-AS1, and sgXLOC_030781 knocked-down 501mel-dCas9-KRAB cells vs. sgROSA negative control and quantification of average sum count cell numbers (n = 2).
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
CRISPRi screen lncRNA hit functional characterization. A, Flow cytometry–based dotmplot showing GFP and mCherry signal as proxy for sgRNA and dCas9 expression (left). 7-AAD fluorescence–dependent cell cycle analysis in 501mel-dCas9-KRAB (top) and WM136a-dCas9-KRAB (bottom) cell lines upon sgBDNF-AS, sgXLOC_030781, and sgGMDS-AS1 CRISPRi knockdown (rigth). Note that the top panel is plotted linear and bottom logarithmic because of better cell cycle–gating parameters. B, Cell cycle phase quantification based on A in percent of cells (n = 2). C, PARP cleavage apoptosis assay performed by Western blotting upon sgBDNF-AS, sgXLOC_030781, and sgGMDS-AS1 knockdown in 501meld-Cas9-KRAB and WM1361a-dCas9-KRAB Representative Western blots (top). GAPDH detection was used as a loading control; densitometric quantification of apoptosis as cleaved PARP/GAPDH protein ratio (bottom; average of n = 2). sgROSA served as negative control and etoposide apoptosis inducer as positive control. D, Re-analysis of 7-AAD cell cycle assay staining using exact same gating parameters for sub-G1 cellular fraction indicative of apoptosis. E, Transwell cell migration assay. Fluorescence photomicrographs show calcein-stained migrated cells of sgBDNF-AS, sgGMDS-AS1, and sgXLOC_030781 knocked-down 501mel-dCas9-KRAB cells vs. sgROSA negative control and quantification of average sum count cell numbers (n = 2).
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Results XLOC_030781 KD RNA-Seq
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Results XLOC_030781 KD RNA-Seq
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Table S3 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Table S3 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Samples and expression values Badal et al and Kunz et al
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Samples and expression values Badal et al and Kunz et al
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
XLOC_030781 CRISPRi knockdown and RNA-sequencing transcriptomic expression analysis
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
XLOC_030781 CRISPRi knockdown and RNA-sequencing transcriptomic expression analysis